Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 24, 2016
Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related DiabetesGregory C Jones, Zhou M Chong, Jennifer Gilmour, et al.BMC Pulmonary Medicine|August 15, 2019
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional studyScott C Bell, Jochen G Mainz, Gordon MacGregor, et al.American Journal of Respiratory and Critical Care Medicine|June 21, 2008
Sputum proteomics in inflammatory and suppurative respiratory diseasesRobert D Gray, Gordon MacGregor, Donald Noble, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 16, 2025
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysisGabriela Vega-Hernandez, Gordon MacGregor, Andrew Wilfin, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 5, 2008
Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluidGordon MacGregor, Robert D Gray, Thomas N Hilliard, et al.ERJ Open Research|October 30, 2020
Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b studySilke van Koningsbruggen-Rietschel, Jane C Davies, Tacjana Pressler, et al.American Journal of Respiratory Cell and Molecular Biology|February 25, 2006
Human-specific cystic fibrosis transmembrane conductance regulator antibodies detect in vivo gene transfer to ovine airwaysHeather Davidson, Gerry McLachlan, Abigail Wilson, et al.Plos One|December 28, 2020
Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trialGraham Devereux, Danielle Wrolstad, Stephen J Bourke, et al.The Lancet. Respiratory Medicine|December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trialSivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 7, 2024
How to: assess patient suitability for unlicensed phage therapy in the United KingdomJoshua D Jones, Helen J Stacey, Ian W Kennedy, et al.Pageof 3